245 related articles for article (PubMed ID: 62010)
1. Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function.
Schreiber RD; Götze O; Müller-Eberhard HJ
J Exp Med; 1976 Oct; 144(4):1062-75. PubMed ID: 62010
[TBL] [Abstract][Full Text] [Related]
2. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.
Medicus RG; Götze O; Müller-Eberhard HJ
J Exp Med; 1976 Oct; 144(4):1076-93. PubMed ID: 978134
[TBL] [Abstract][Full Text] [Related]
3. A molecular concept of the properdin pathway.
Medicus RG; Schreiber RD; Götze O; Müller-Eberhard HJ
Proc Natl Acad Sci U S A; 1976 Feb; 73(2):612-6. PubMed ID: 54923
[TBL] [Abstract][Full Text] [Related]
4. Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor.
Schreiber RD; Medicus RG; Gïtze O; Müller-Eberhard HJ
J Exp Med; 1975 Sep; 142(3):760-72. PubMed ID: 1165475
[TBL] [Abstract][Full Text] [Related]
5. C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.
Whaley K; Schur PH; Ruddy S
J Clin Invest; 1976 Jun; 57(6):1554-63. PubMed ID: 819459
[TBL] [Abstract][Full Text] [Related]
6. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase.
Fearon DT; Austen KF
J Exp Med; 1975 Oct; 142(4):856-63. PubMed ID: 1185108
[TBL] [Abstract][Full Text] [Related]
7. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins.
Fearon DT; Austen KF
J Exp Med; 1977 Jul; 146(1):22-33. PubMed ID: 559720
[TBL] [Abstract][Full Text] [Related]
8. Properdin: initiation of alternative complement pathway.
Fearon DT; Austen KF
Proc Natl Acad Sci U S A; 1975 Aug; 72(8):3220-4. PubMed ID: 1059108
[TBL] [Abstract][Full Text] [Related]
9. Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy.
Michels MAHM; van de Kar NCAJ; van den Bos RM; van der Velden TJAM; van Kraaij SAW; Sarlea SA; Gracchi V; Oosterveld MJS; Volokhina EB; van den Heuvel LPWJ
Front Immunol; 2019; 10():1350. PubMed ID: 31263464
[TBL] [Abstract][Full Text] [Related]
10. Nephritic factor: its structure and function and its relationship to initiating factor of the alternative pathway.
Schreiber RD; Götze O; Müller-Eberhard HJ
Scand J Immunol; 1976; 5(6-7):705-13. PubMed ID: 62386
[TBL] [Abstract][Full Text] [Related]
11. Isolation and characterization of Guinea pig properidin.
Nicholson A; Austen KF
J Immunol; 1977 Jan; 118(1):103-8. PubMed ID: 830742
[TBL] [Abstract][Full Text] [Related]
12. Control of the amplification convertase of complement by the plasma protein beta1H.
Weiler JM; Daha MR; Austen KF; Fearon DT
Proc Natl Acad Sci U S A; 1976 Sep; 73(9):3268-72. PubMed ID: 1067618
[TBL] [Abstract][Full Text] [Related]
13. The utilization of properdin in the alternate pathway of complement activation: isolation of properdin convertase.
Stitzel AE; Spitzer RE
J Immunol; 1974 Jan; 112(1):56-62. PubMed ID: 4130153
[No Abstract] [Full Text] [Related]
14. Association of activated properdin with complexes of properdin with C3.
Whiteman LY; Purkall DB; Ruddy S
J Immunol; 1991 Aug; 147(4):1344-51. PubMed ID: 1869827
[TBL] [Abstract][Full Text] [Related]
15. Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms.
Fearon DT; Austen KF
Proc Natl Acad Sci U S A; 1977 Apr; 74(4):1683-7. PubMed ID: 266208
[TBL] [Abstract][Full Text] [Related]
16. Hypocomplementemia of membranoproliferative nephritis. Dependence of the nephritic factor reaction on properdin factor B.
Ruley EJ; Forristal J; Davis NC; Andres C; West CD
J Clin Invest; 1973 Apr; 52(4):896-904. PubMed ID: 4693654
[TBL] [Abstract][Full Text] [Related]
17. Reversible activation of proactivator (factor B) of the alternative pathway without cleavage of the molecule.
Day NK; Schreiber RD; Götze O; Müller-Eberhard HJ
Scand J Immunol; 1976; 5(6-7):715-20. PubMed ID: 981969
[TBL] [Abstract][Full Text] [Related]
18. The alternative pathway of complement activation.
Götze O; Müller-Eberhard HJ
Adv Immunol; 1976; 24():1-35. PubMed ID: 798473
[No Abstract] [Full Text] [Related]
19. Interaction of zymosan and of activated properdin with factor D-depleted guinea pig serum: implications for the mechanism of initial C3 cleavage via the alternative complement pathway.
Brade V; Bentley C; Bitter-Suermann D; Hadding U
Z Immunitatsforsch Immunobiol; 1977 Feb; 152(5):402-14. PubMed ID: 556571
[TBL] [Abstract][Full Text] [Related]
20. Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via the properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid.
Vogt W; Schmidt G; Lynen R; Dieminger L
J Immunol; 1975 Feb; 114(2 Pt 1):671-7. PubMed ID: 804510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]